These guys must be desperate for product candidates or are unaware that Genasense already failed for melanoma.
My bet is that the T-oligo gets chewed up in the bloodstream (a la genasense) before it even attempts to enter cells... which it really can't because it is a standard charged oligo.
Man, i gotta stop working on cardiovascular stuff and start working on cancer. Lots of opportunities to make easy research dollars from desperate oncology companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.